Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce A Feinberg

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practiceRodolfo E Bordoni, Bruce A Feinberg, James W Gilmore, et al.
Future Oncology (London, England)|December 6, 2019
Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancerKellie J Ryan, Damion Nero, Bruce A Feinberg, et al.
Future Oncology (London, England)|February 26, 2019
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world studyJason J Luke, Sameer R Ghate, Jonathan Kish, et al.
Medical Oncology (Northwood, London, England)|April 12, 2011
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinicsBruce A Feinberg, Pradeep Jolly, Si-Tien Wang, et al.
Immunotherapy|August 19, 2020
Neurological adverse events following CAR T-cell therapy: a real-world analysisAjeet Gajra, Marjorie E Zettler, Eli G Phillips, et al.
Cancer Medicine|August 2, 2018
Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology settingSarah S Mougalian, Ronda Copher, Jonathan K Kish, et al.
Journal of Medical Economics|April 7, 2022
Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19Scott Gibson, Rhodri Saunders, Nathan Stasko, et al.
The American Journal of Managed Care|June 15, 2012
Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providersBruce A Feinberg, James Lang, James Grzegorczyk, et al.
Future Oncology (London, England)|October 30, 2019
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapySarah S Mougalian, Bruce A Feinberg, Edward Wang, et al.
The American Journal of Managed Care|September 27, 2012
Implementation of cancer clinical care pathwaysBruce A Feinberg, James Lang, James Grzegorczyk, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practiceRodolfo E Bordoni, Bruce A Feinberg, James W Gilmore, et al.
Future Oncology (London, England)|December 6, 2019
Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancerKellie J Ryan, Damion Nero, Bruce A Feinberg, et al.
Future Oncology (London, England)|February 26, 2019
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world studyJason J Luke, Sameer R Ghate, Jonathan Kish, et al.
Medical Oncology (Northwood, London, England)|April 12, 2011
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinicsBruce A Feinberg, Pradeep Jolly, Si-Tien Wang, et al.
Immunotherapy|August 19, 2020
Neurological adverse events following CAR T-cell therapy: a real-world analysisAjeet Gajra, Marjorie E Zettler, Eli G Phillips, et al.
Cancer Medicine|August 2, 2018
Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology settingSarah S Mougalian, Ronda Copher, Jonathan K Kish, et al.
Journal of Medical Economics|April 7, 2022
Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19Scott Gibson, Rhodri Saunders, Nathan Stasko, et al.
The American Journal of Managed Care|June 15, 2012
Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providersBruce A Feinberg, James Lang, James Grzegorczyk, et al.
Future Oncology (London, England)|October 30, 2019
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapySarah S Mougalian, Bruce A Feinberg, Edward Wang, et al.
The American Journal of Managed Care|September 27, 2012
Implementation of cancer clinical care pathwaysBruce A Feinberg, James Lang, James Grzegorczyk, et al.
Pageof 5